HK87596A - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds Download PDF

Info

Publication number
HK87596A
HK87596A HK87596A HK87596A HK87596A HK 87596 A HK87596 A HK 87596A HK 87596 A HK87596 A HK 87596A HK 87596 A HK87596 A HK 87596A HK 87596 A HK87596 A HK 87596A
Authority
HK
Hong Kong
Prior art keywords
compound
methyl
formula
thieno
mol
Prior art date
Application number
HK87596A
Other languages
German (de)
English (en)
Inventor
Kumar Chakrabarti Jiban
Michael Hotten Terrence
Edward Tupper David
Original Assignee
Eli Lilly And Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK87596(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company Limited filed Critical Eli Lilly And Company Limited
Publication of HK87596A publication Critical patent/HK87596A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Claims (22)

1. Procédé pour la production de la 2-méthyl-10-(4-méthyl-1-pipérazinyl)-4H-thiéno[2,3-b][1,5]-benzodiazépine, ou d'un sel acide de celle-ci, qui comprend :
(a) la mise en réaction de la N-méthylpipérazine avec un composé répondant à la formule dans laquelle Q est un radical susceptible d'être éliminé, ou
(b) la fermeture du cycle d'un composé répondant à la formule
2. Procédé pour la production de la 2-méthyl-10-(4-méthyl-1-pipérazinyl)-4H-thiéno[2,3-b][1,5]-benzodiazépine, ou d'un sel acide de celle-ci, qui comprend la mise en réaction de la N-méthylpipérazine avec un composé répondant à la formule dans laquelle Q représente -NH2, -OH ou -SH, et lorsque Q représente -NH2, les sels de celle-ci.
3. Procédé selon la revendication 2, qui comprend la mise en réaction d'un composé dans lequel Q représente -NH2 ou un sel de celui-ci.
4. Procédé selon l'une ou l'autre des revendications 2 et 3, qui est effectué à une température de 50 ° C à 200 ° C.
5. Composé répondant à la formule dans laquelle Q représente -NH2, -OH ou -SH, et lorsque Q représente - NH2, les sels de celui-ci.
6. Composé selon la revendication 5, dans lequel Q représente -NH2, ou un sel de celui-ci.
HK87596A 1990-04-25 1996-05-16 Pharmaceutical compounds HK87596A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009229A GB9009229D0 (en) 1990-04-25 1990-04-25 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
HK87596A true HK87596A (en) 1996-05-24

Family

ID=10674942

Family Applications (1)

Application Number Title Priority Date Filing Date
HK87596A HK87596A (en) 1990-04-25 1996-05-16 Pharmaceutical compounds

Country Status (33)

Country Link
EP (1) EP0454436B1 (fr)
JP (1) JP2527860B2 (fr)
KR (1) KR100195566B1 (fr)
CN (1) CN1028429C (fr)
AT (1) ATE127804T1 (fr)
AU (1) AU643267B2 (fr)
BG (1) BG61710B2 (fr)
CA (1) CA2041113C (fr)
CY (1) CY1900A (fr)
CZ (1) CZ279937B6 (fr)
DE (3) DE69112895T4 (fr)
DK (1) DK0454436T3 (fr)
ES (1) ES2078440T3 (fr)
FI (1) FI101379B (fr)
GB (1) GB9009229D0 (fr)
GE (1) GEP20032965B (fr)
GR (1) GR3017877T3 (fr)
HK (1) HK87596A (fr)
HU (2) HU212416B (fr)
IE (1) IE68401B1 (fr)
IL (2) IL97912A (fr)
LU (2) LU90009I2 (fr)
LV (1) LV10262B (fr)
MX (1) MX173791B (fr)
NL (2) NL970015I2 (fr)
NO (3) NO178766C (fr)
NZ (1) NZ237932A (fr)
PT (1) PT97446B (fr)
RU (1) RU2043992C1 (fr)
SI (1) SI9110739A (fr)
SK (1) SK279196B6 (fr)
YU (1) YU48049B (fr)
ZA (1) ZA913085B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817656A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5817657A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
DE69329887T2 (de) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US6034078A (en) * 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
EP0733368A1 (fr) * 1995-03-24 1996-09-25 Eli Lilly And Company Formulations d'olanzapine granulaires
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CN1131035C (zh) * 1995-05-30 2003-12-17 伊莱利利公司 治疗识别机能障碍的方法
ATE220550T1 (de) * 1995-05-30 2002-08-15 Lilly Co Eli Verfahren zur behandlung von wahrnehmungsstörungen
US6506746B2 (en) 1995-05-30 2003-01-14 Eli Lilly And Company Method for treating cognitive dysfunction
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
AU1335397A (en) * 1995-12-21 1997-07-17 Eli Lilly And Company Method for treating dermatitis
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
AU739385B2 (en) 1997-09-02 2001-10-11 Mitsubishi Pharma Corporation Condensed thiophene compounds and pharmaceutical use thereof
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
AU752552C (en) * 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
CA2420987A1 (fr) 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Procede de preparation d'hydrates d'olanzapine et de conversion de ceux-ci en formes cristallines d'olanzapine
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CH695862A5 (fr) * 2001-12-24 2006-09-29 Sun Pharmaceutical Ind Ltd Forme cristalline I de la methyl-4-(4-methyl-1-piperazinyl) 10H-thieno [2,3-b] [1,5] benzodiazepine.
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
AU2003239967A1 (en) * 2002-06-05 2003-12-22 Ivax Corporation Compound for the treatment of cns disorders
PL199016B1 (pl) * 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) * 2003-01-17 2004-09-16 Krka Tovarna Zdravil, D.D. Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
WO2005063771A1 (fr) 2003-12-22 2005-07-14 Teva Pharmaceutical Industries Ltd Methodes de preparation de l'olanzapine
EP1720885A1 (fr) * 2004-01-27 2006-11-15 Synthon B.V. Procede de fabrication d'olanzapine sous forme polymorphe i
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
EP2623095A1 (fr) * 2004-11-16 2013-08-07 Elan Pharma International Limited Formulations injectables de nanoparticules d'olanzapine
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
EP1838716B1 (fr) 2005-01-05 2011-06-01 Eli Lilly And Company Dihydrate d'olanzapine pamoate
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) * 2006-09-11 2008-04-23 杭州盛美医药科技开发有限公司 一种奥氮平的中间体及其制备与应用
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (fr) 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Procedes ameliores pour la synthese de l'olanzapine
CN101168544B (zh) * 2007-11-16 2010-11-17 西南合成制药股份有限公司 奥氮平的制备工艺
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
CN102532158A (zh) * 2010-12-17 2012-07-04 北大方正集团有限公司 一种合成奥氮平的方法
EP2486913A1 (fr) 2011-02-14 2012-08-15 Labtec GmbH Formulation de film oral à désintégration rapide pour olanzapine
WO2012153347A2 (fr) 2011-05-04 2012-11-15 Zentiva K.S. Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
CN102225941B (zh) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 抗精神病药奥氮平的制备方法
WO2013066280A1 (fr) * 2011-10-31 2013-05-10 Mahmut Bilgic Formulations antipsychotiques hydrosolubles
JP5934004B2 (ja) * 2012-03-22 2016-06-15 株式会社トクヤマ 結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
US20150216206A1 (en) 2012-07-31 2015-08-06 Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi Method for increasing meat and milk production
EA201590048A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение оланзапина у животных
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
KR101641902B1 (ko) 2015-06-24 2016-07-22 주식회사 네이처센스 농업회사법인 스트레스의 완화용 조성물
CN106265541A (zh) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 一种注射用奥氮平及其制备方法
CN111004210A (zh) * 2019-10-23 2020-04-14 中山大学 化合物单晶及其制备方法
WO2025056094A1 (fr) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 Préparation lyophilisée, injection, et procédé de préparation associé

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) * 1975-11-24 1978-11-22 Lilly Industries Ltd Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) * 1977-05-17 1980-10-29 Lilly Industries Ltd Benzodiazepine derivatives

Also Published As

Publication number Publication date
NL970015I1 (nl) 1997-06-02
EP0454436B1 (fr) 1995-09-13
NL970015I2 (nl) 1997-09-01
KR100195566B1 (ko) 1999-06-15
ES2078440T3 (es) 1995-12-16
EP0454436A1 (fr) 1991-10-30
KR910018387A (ko) 1991-11-30
PT97446B (pt) 1997-07-31
JP2527860B2 (ja) 1996-08-28
NO911624L (no) 1991-10-28
CN1056693A (zh) 1991-12-04
IE68401B1 (en) 1996-06-12
NZ237932A (en) 1993-08-26
SI9110739A (en) 1997-10-31
NO178766B (no) 1996-02-19
DE19675046I2 (de) 2001-05-23
DE69112895T4 (de) 2009-11-12
ZA913085B (en) 1992-12-30
CS9101168A2 (en) 1991-12-17
NO1997005I1 (no) 1997-05-12
CN1028429C (zh) 1995-05-17
NO178766C (no) 1996-05-29
FI101379B1 (fi) 1998-06-15
CZ279937B6 (cs) 1995-09-13
GEP20032965B (en) 2003-05-12
RU2043992C1 (ru) 1995-09-20
LU90869I2 (fr) 2002-02-21
FI911986A0 (fi) 1991-04-24
LV10262A (lv) 1994-10-20
DE69112895D1 (de) 1995-10-19
IL97912A0 (en) 1992-06-21
HUT60503A (en) 1992-09-28
HU911372D0 (en) 1991-10-28
HU212416B (en) 1996-06-28
NO2001028I1 (no) 2002-01-28
LU90009I2 (fr) 1997-01-31
GR3017877T3 (en) 1996-01-31
AU7518691A (en) 1991-11-07
CA2041113C (fr) 1998-07-14
CA2041113A1 (fr) 1991-10-26
IL112575A0 (en) 1995-05-26
YU48049B (sh) 1996-10-18
SK279196B6 (sk) 1998-07-08
IL97912A (en) 1995-10-31
AU643267B2 (en) 1993-11-11
JPH0789965A (ja) 1995-04-04
IE911348A1 (en) 1991-11-06
BG61710B2 (bg) 1998-03-31
NO911624D0 (no) 1991-04-24
DK0454436T3 (da) 1995-11-13
ATE127804T1 (de) 1995-09-15
YU73991A (sh) 1994-01-20
GB9009229D0 (en) 1990-06-20
FI911986L (fi) 1991-10-26
MX173791B (es) 1994-03-25
HU211575A9 (en) 1995-12-28
LV10262B (en) 1995-04-20
DE69112895T2 (de) 1996-03-07
MX25502A (es) 1993-10-01
PT97446A (pt) 1992-01-31
CY1900A (en) 1991-04-24
NL300078I1 (nl) 2002-03-01
FI101379B (fi) 1998-06-15

Similar Documents

Publication Publication Date Title
EP0454436B1 (fr) Composés pharmaceutiques
US5229382A (en) 2-methyl-thieno-benzodiazepine
US6008216A (en) Process for preparing 2-methyl-thieno-benzodiazepine
US5605897A (en) 2-methyl-thieno-benzodiazepine
US5817656A (en) Mental disorders
US5817655A (en) Methods of treatment using a thieno-benzodiazepine
EP0582368A1 (fr) Dérivés de thienobenzodiazépine pour le traitement des troubles du système nerveux central
US5817657A (en) Psychoactive substance disorders
EP0874625B1 (fr) Derives d'indane destines a des compositions antipsychotiques
US5051516A (en) Benzodiazepine compounds and their use as pharmaceuticals
CA1321996C (fr) Diazepinones condenses, methodes de preparation et compositions pharmaceutiques a base de diazepinones
EP0828494B1 (fr) Procede de traitement du dysfonctionnement cognitif
SA95160196B1 (ar) مركبات صيدلانية
NZ502237A (en) 3-substituted pyrido [3',4':4,5] thieno [2,3-d] pyrimidine derivatives for treating 5-HT1B/D receptor related disorders which increases serotonin release in the brain
US20020177590A1 (en) Method for treating cognitive dysfunction
NZ240501A (en) 4- or 5-(2-nitroanilino)thiazole derivatives
CA2219902A1 (fr) Utilisation du 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine pour le traitement du dysfonctionnement cognitif
HK1009393B (en) Method for treating cognitive dysfunction

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20110423